Inositol — specifically myo-inositol, the most biologically active form — is a simple sugar alcohol that is a critical component of the phosphatidylinositol (PI) second messenger system, one of the primary signalling pathways by which cells respond to hormonal and neurotransmitter signals. Every cell in the body uses the PI pathway for signal transduction, but it is particularly important in neurons, where it mediates the effects of serotonin (5-HT2 receptors), noradrenaline (alpha-1 adrenergic receptors), acetylcholine (muscarinic M1, M3 receptors), and glutamate (metabotropic glutamate receptors). Inositol is not a neurotransmitter, but it is the substrate without which these neurotransmitter signalling pathways cannot function.
The Phosphatidylinositol Signalling Cascade
The phosphatidylinositol signalling cascade begins when a neurotransmitter binds to a G-protein-coupled receptor (GPCR) that is coupled to the Gq protein. The activated Gq protein then activates phospholipase C (PLC), which cleaves the membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 diffuses to the endoplasmic reticulum and triggers the release of calcium ions into the cytoplasm; DAG activates protein kinase C (PKC), which phosphorylates target proteins that alter cell function.
In the brain, this cascade is the mechanism by which serotonin produces its behavioural effects — particularly the 5-HT2A receptor subtype, which is the primary mediator of the psychedelic experience and also a target for the anxiolytic and antidepressant effects of certain serotonergic drugs. The behavioural effects of psychedelic therapy are driven precisely by the activation of this pathway in cortical neurons. Low inositol levels would be expected to dampen this signalling cascade, potentially contributing to the serotonin-dysregulation model of depression.
Clinical Evidence: OCD, Panic Disorder, and Depression
Myo-inositol has been studied in several clinical trials for psychiatric conditions with promising results. The most robust evidence is for Obsessive-Compulsive Disorder (OCD): a double-blind crossover RCT in 10 patients with OCD found that myo-inositol at 18g daily was as effective as the SSRI fluvoxamine (150mg daily) in reducing OCD symptoms on the Yale-Brown Obsessive Compulsive Scale, with a faster onset of action and fewer side effects. This is a striking result given that OCD is notoriously difficult to treat pharmacologically — most patients require SSRI doses 2-3 times higher than the standard depression dose.
For panic disorder, a double-blind RCT in 21 patients found that myo-inositol at 12g daily significantly reduced the frequency and severity of panic attacks compared to placebo over 4 weeks. The effect size was comparable to theSSRI fluvoxamine but with fewer side effects. For depression, the evidence is more mixed — some studies show benefit in mild to moderate depression, particularly in people with low baseline inositol levels, while others show no significant effect. Inositol is generally considered a second-line intervention for depression after standard pharmacotherapy has been tried.
Inositol for Polycystic Ovary Syndrome (PCOS)
Beyond its psychiatric applications, inositol has been extensively studied in women with Polycystic Ovary Syndrome (PCOS), where insulin resistance and hyperinsulinaemia play a central pathophysiological role. In PCOS, thePI3K pathway (which is also inositol-dependent) is impaired in ovarian theca cells, leading to excessive androgen production and the characteristic hormonal profile of PCOS. Myo-inositol (and its isomer D-chiro-inositol) improve insulin sensitivity through the PI3K pathway, reducing ovarian androgen production and improving ovulation rates.
A meta-analysis of 10 RCTs in women with PCOS found that myo-inositol at 2-4g daily significantly improved ovulation rates, reduced free testosterone, and improved insulin sensitivity compared to placebo, with effects comparable to metformin but with a better side-effect profile. The combination of myo-inositol (2g) and D-chiro-inositol (50mg) in a specific ratio that mimics the physiological ratio in the body appears to be the most effective formulation. This makes inositol one of the most evidence-based nutritional interventions for women with PCOS.
Dosing, Safety, and Interactions
The evidence-based dose varies by condition: for OCD, 12-18g daily of myo-inositol powder (the dose used in the OCD trials); for panic disorder, 12g daily; for PCOS, 2-4g daily of myo-inositol (often combined with D-chiro-inositol). Inositol is generally well-tolerated with occasional GI discomfort (mild diarrhea) at higher doses. It has no significant drug interactions and is safe for long-term use at these doses. The powder form is inexpensive and can be mixed with water or juice.
A quality supplement routine can make a real difference to your results.
Leave a Reply